华安证券：小核酸递送技术突破及适应症延伸建议持续关注siRNA赛道

智通财经01-19

智通财经APP获悉，华安证券发布研报称，小核酸技术及适应症限制突破，从罕见疾病及心血管疾病，到减重等重大代谢领域以及CNS甚至肿瘤领域的延伸。海外产品进入商业化验证阶段，海内外产业趋势共振，国内布局公司有望获得资本市场受益，进而加速技术更新及管线推进，持续关注小核酸领域投资机会，建议持续关注siRNA赛道。华安证券主要观点如下：标志性事件海外，跨国药企诺华在2025年大举布局小核酸，单年3笔BD...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2604185899?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-19 15:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604185899","market":"fut","top_or_hot":-1,"title":"华安证券：小核酸递送技术突破及适应症延伸 建议持续关注siRNA赛道","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，华安证券发布研报称，小核酸技术及适应症限制突破，从罕见疾病及心血管疾病，到减重等重大代谢领域以及CNS甚至肿瘤领域的延伸。海外产品进入商业化验证阶段，海内外产业趋势共振，国内布局公司有望获得资本市场受益，进而加速技术更新及管线推进，持续关注小核酸领域投资机会，建议持续关注siRNA赛道。华安证券主要观点如下：标志性事件海外，跨国药企诺华在2025年大举布局小核酸，单年3笔BD...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1394451.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华安证券：小核酸递送技术突破及适应症延伸 建议持续关注siRNA赛道</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华安证券：小核酸递送技术突破及适应症延伸 建议持续关注siRNA赛道\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-19 15:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1394451.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，华安证券发布研报称，小核酸技术及适应症限制突破，从罕见疾病及心血管疾病，到减重等重大代谢领域以及CNS甚至肿瘤领域的延伸。海外产品进入商业化验证阶段，海内外产业趋势共振，国内布局公司有望获得资本市场受益，进而加速技术更新及管线推进，持续关注小核酸领域投资机会，建议持续关注siRNA赛道。华安证券主要观点如下：标志性事件海外，跨国药企诺华在2025年大举布局小核酸，单年3笔BD...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1394451.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1394451.html","article_id":"2604185899","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604185899","pubTimestamp":1768807593,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，华安证券发布研报称，小核酸技术及适应症限制突破，从罕见疾病及心血管疾病，到减重等重大代谢领域以及CNS甚至肿瘤领域的延伸。海外产品进入商业化验证阶段，海内外产业趋势共振，国内布局公司有望获得资本市场受益，进而加速技术更新及管线推进，持续关注小核酸领域投资机会，建议持续关注siRNA赛道。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600909":"华安证券","BK0183":"MSCI概念","BK0276":"资本市场","BK0201":"可转债"},"translate_title":"Huaan Securities: Breakthroughs in small nucleic acid delivery technology and extension of indications are recommended to continue to pay attention to the siRNA track","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600909":1.5},"content_text":"智通财经APP获悉，华安证券发布研报称，小核酸技术及适应症限制突破，从罕见疾病及心血管疾病，到减重等重大代谢领域以及CNS甚至肿瘤领域的延伸。海外产品进入商业化验证阶段，海内外产业趋势共振，国内布局公司有望获得资本市场受益，进而加速技术更新及管线推进，持续关注小核酸领域投资机会，建议持续关注siRNA赛道。华安证券主要观点如下：标志性事件海外，跨国药企诺华在2025年大举布局小核酸，单年3笔BD交易及一笔120亿美元收购案震动业内，其上市产品Inclisiran在2025H1取得5.55亿美元的销售额(同比+66%)，其位于瑞士的Schweizerhalle基地近日获得8000万美元的投资，用于扩大siRNA生产规模;小核酸企业Arrowhead旗下Plozasirna开启商业化，后公布ARO-INHBE和ARO-ALK7积极临床数据;Wave Life Science的INHBE siRNA增肌减脂药物WVE-007数据优异，使siRNA成为GLP-1之后的减重分子新方向;国内，舶望制药对诺华的50亿美金总额out licensing，打破非肿瘤领域的BD交易金额记录;诺华旗下siRNA药物Inclisiran被正式纳入我国2025年医保目录，小核酸正式成为具备商业化+BD驱动逻辑的技术赛道。技术迭代应用拓展递送技术方面，逐步实现从肝靶向到跨脑递送、肺靶向等肝外靶向的技术突破;适应症方面，从罕见疾病及心血管疾病，到减重等重大代谢领域以及CNS甚至肿瘤领域的延伸。药物靶点布局成熟靶点方面，继Inclisiran(PCSK9前蛋白转化酶枯草溶菌素9)在2020年首次获批，开启siRNA在心血管领域的应用后，ApoC3(载脂蛋白C3)、Lpa(脂蛋白a)、ANGPTL3(血管生成素样3)等调脂治疗相关靶点成为药企在研“标配”，AGT(血管紧张素原)、FXI(凝血因子XI)深化高血压、血栓疾病应用。新兴靶点方面，INHBE(抑制素亚基βE)、ALK7在肥胖初步数据披露、PNPLA3等在MASH的发展、C3等在补体相关疾病、IgA肾病管线增加，持续扩大siRNA的应用范围及前景。风险提示：新药临床研发失败的风险、BD谈判进度不及预期、技术发展不及预期的风险","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604185899","isCrawlerRequest":true}

华安证券：小核酸递送技术突破及适应症延伸 建议持续关注siRNA赛道

精彩评论

华安证券：小核酸递送技术突破及适应症延伸建议持续关注siRNA赛道